Patents by Inventor Roman Thomas
Roman Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240327928Abstract: The present invention pertains to a method for identifying a subject suffering from cancer as a responder or non-responder to fibroblast growth factor receptor 1 (FGFR1) inhibitor therapy. The method involves the determination of the presence or absence of a genetic alteration of the FGFR1 gene, wherein the genetic variation is a copy number variation caused by a Breakage-Fusion-Bridge-like (BFB-like) mechanism wherein the break is located within, or within close proximity of, the ORF of the FGFR1 gene. These breaks associate with FGFR inhibitor sensitivity, and intra-chromosomal tail-to-tail breaks in FGFR1 may work as a predictive therapeutic marker for an FGFR inhibitor therapy in cancer that can be used to stratify patients for FGFR-inhibitor therapy. Furthermore, provided are inhibitors of FGFR1 for use in the treatment of cancer, and a method for identifying a genetic biomarker associated with a disorder, such as cancer.Type: ApplicationFiled: August 11, 2022Publication date: October 3, 2024Inventors: Florian MALCHERS, Roman THOMAS
-
Patent number: 10208354Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.Type: GrantFiled: August 7, 2014Date of Patent: February 19, 2019Assignee: Universität zu KölnInventors: Lynnette Fernandez-Cuesta, Julie George, Dennis Plenker, Roman Thomas
-
Patent number: 10131177Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.Type: GrantFiled: February 7, 2014Date of Patent: November 20, 2018Assignee: ENTRUST DATACARD CORPORATIONInventors: Roman Thomas Knipp, Peter Daniel Schmidt
-
Publication number: 20170228632Abstract: Systems and methods wherein one or more processing operations on an identification document occur after a radiation curable material is applied to a surface of the identification document but before the radiation curable material is fully cured. The one or more processing operations can occur before any curing of the radiation curable material takes place. Alternatively, the one or more processing operations can occur after the radiation curable material has been partially cured, and before the radiation curable material is fully or completely cured.Type: ApplicationFiled: February 3, 2017Publication date: August 10, 2017Inventors: Roman Thomas KNIPP, Pauline UKPABI, Utpal R. VAIDYA, Thomas J. WAGENER, Brian BEECH
-
Publication number: 20160312288Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.Type: ApplicationFiled: August 7, 2014Publication date: October 27, 2016Applicant: Universität zu KölnInventors: Lynnette FERNANDEZ-CUESTA, Julie GEORGE, Dennis PLENKER, Roman THOMAS
-
Publication number: 20150329537Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.Type: ApplicationFiled: August 22, 2012Publication date: November 19, 2015Applicants: LEADDISCOVERY CENTER GMBH, MAX-PLANCK GESELLSCHAFTZUR FORDERUNG DER WIS SENSCHAFTEN E.VInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20150224810Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.Type: ApplicationFiled: February 7, 2014Publication date: August 13, 2015Applicant: DATACARD CORPORATIONInventors: Roman Thomas KNIPP, Peter Daniel SCHMIDT
-
Publication number: 20140303167Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.Type: ApplicationFiled: August 22, 2012Publication date: October 9, 2014Applicant: LEAD DISCOVERY CENTER GMBHInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20140287454Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.Type: ApplicationFiled: August 22, 2012Publication date: September 25, 2014Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbHInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20130023420Abstract: The present invention relates to a combination of cell lines as well as a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor anti-tumor agent. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell or collection of cells or cell lines to treatment with a drug such as an HSP90 inhibitor anti-tumor agent is described herein.Type: ApplicationFiled: February 14, 2012Publication date: January 24, 2013Inventors: Roman Thomas, Kathrin Maring, Thomas Zander, Peter Frommolt, Kwok-kin Wong
-
Publication number: 20110319415Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and.Type: ApplicationFiled: August 17, 2009Publication date: December 29, 2011Applicants: Universit+e,uml a+ee t zu K+e,uml o+ee ln, Max-Planck-Gesellschaft zur F+e,uml o+ee rderung der WissensInventors: Roman Thomas, Kathrin Maring, Thomas Zander, Peter Frommolt, Kwok-kin Wong
-
Patent number: 6964530Abstract: A system and method are provided for correcting a hang condition caused by an unanticipated exception during a printing process. The method may include providing a set of predetermined rules according to which the print process modules interact to control the printing process. The method further may include monitoring, from a self-correcting module, a state of each of a plurality of the print process modules. The method may also include determining that the printing device is hung during a printing process, based on at least one predetermined rule and the state of at least one print process module, and setting the state of at least one print process module to a default condition.Type: GrantFiled: January 23, 2004Date of Patent: November 15, 2005Assignee: Hewlett-Packard Development Company, L.P.Inventors: Nataraj Kumar Gobbak, Jeetendra Kumar, Roman Thomas Wachter